Trial Profile
Safety and efficacy of FTY720 in adult patients who receive a kidney transplant.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Feb 2017
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 14 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Nov 2011 Planned end date (Mar 2006) added as reported by ClinicalTrials.gov.
- 29 Nov 2005 New trial record.